Medicine News
Latest pharmaceutical research, drug approvals, medication safety updates, and treatment breakthroughs from iMedic.
Articles
-
FDA Approves Sparsentan as First-Ever Treatment for Focal Segmental Glomerulosclerosis
The FDA has approved sparsentan (Filspari) as the first treatment specifically indicated for FSGS, a rare kidney disease with no prior approved therapies.
-
Gestational Diabetes and Insulin Resistance: How Blood Sugar Regulation During Sleep Affects Outcomes
New insights into gestational diabetes insulin treatment and how nocturnal blood sugar regulation impacts insulin resistance and maternal-fetal outcomes.
-
GLP-1 Drugs for Weight Loss: How Semaglutide and Tirzepatide Are Reshaping Medicine
GLP-1 receptor agonists like semaglutide and tirzepatide are transforming weight loss treatment and showing benefits for heart, kidney, and liver disease.
-
GLP-1 Drugs May Improve Liver Health Independent of Weight Loss, New Research Suggests
New mouse study finds GLP-1 receptor agonists improve liver health through mechanisms beyond weight loss, offering hope for NAFLD treatment.
-
Menopause Drug Market Surges: New Nonhormonal Therapies Transform Treatment Options
The menopause drug market is experiencing unprecedented growth as new nonhormonal therapies like fezolinetant join HRT options, giving women more treatment choi
-
Topical Treatments for Rheumatoid Arthritis Joint Pain: What Works and What Doesn't
Evidence-based guide to topical treatments for rheumatoid arthritis joint pain, including NSAIDs, capsaicin, and emerging therapies.
-
Sulthiame for Sleep Apnea: Clinical Trial Shows Drug Reduces Night-Time Breathing Pauses
A clinical trial finds sulthiame, a carbonic anhydrase inhibitor, significantly reduces breathing pauses in obstructive sleep apnea patients unable to tolerate
-
GLP-1 Weight Loss and Side Effects Linked to Genetic Variations: What It Means for Patients
New research links genetic variations to how patients respond to GLP-1 receptor agonists, explaining differences in weight loss outcomes and side effects.
-
Probiotics May Boost GLP-1 Drug Effectiveness in Obesity Treatment, New Research Suggests
New research suggests probiotics could enhance the weight loss effects of GLP-1 receptor agonists like semaglutide by improving gut microbiome composition.
-
FDA Regulatory Reform: What New Accelerated Approval Changes Mean for Patients
FDA accelerated approval pathway faces major reforms. Learn how regulatory changes affect drug access, confirmatory trials, and patient safety.
-
23andMe Identifies Genetic Markers That May Predict GLP-1 Drug Response for Weight Loss
23andMe research identifies genetic variants linked to how patients respond to GLP-1 weight loss drugs like semaglutide, advancing pharmacogenomics.
-
Jaw Cramps and Hypoglycemia: The Overlooked Warning Sign in Type 2 Diabetes
Jaw cramps can signal dangerously low blood sugar in people with type 2 diabetes on insulin. Learn why this symptom occurs and how to manage hypoglycemia safely
-
GLP-1 Weight-Loss Drugs May Relieve Arthritis Pain: What Doctors Are Finding
Doctors report GLP-1 weight-loss medications like semaglutide may reduce arthritis pain through anti-inflammatory effects beyond weight reduction alone.
-
Human Insulin for Diabetes: Why Doctors Are Revisiting Regular R Insulin
Regular human insulin (R insulin) is gaining renewed attention for diabetes management. Learn why some physicians advocate for its use alongside modern analogs.
-
Inhaled RNA Therapy Shows Promise for Reducing Lung Inflammation After Severe Infections
New inhaled RNA-based treatment reduces lung inflammation in preclinical models, offering hope for post-infection respiratory damage.
-
Weight Regain After Stopping Obesity Medication: What the Evidence Shows
A BMJ systematic review reveals how much weight people regain after discontinuing weight management medications like GLP-1 receptor agonists.
-
FDA Food and Dietary Supplement Labeling: What Health Claims Are Actually Allowed?
Understanding FDA regulation of health claims on food and dietary supplement labels, including the difference between approved and unauthorized claims.
-
FDA's New Drug Pricing Role: How Cost Considerations Could Reshape Approvals
The FDA's expanding role in drug pricing adds new uncertainty to the approval process. What this means for pharmaceutical companies and patients.
-
GLP-1 Weight-Loss Drug Side Effects: What Is 'Ozempic Face' and How to Manage It
GLP-1 drugs like semaglutide cause side effects beyond nausea. Learn about 'Ozempic face,' muscle loss, and how to reduce risks during treatment.
-
Genetic Variants in 1 in 10 People May Blunt GLP-1 Drug Response for Diabetes
New research finds common genetic variants may reduce how well GLP-1 receptor agonists lower blood sugar, pointing toward pharmacogenomic prescribing.
-
Oral Semaglutide vs. Orforglipron: How Do These Weight Loss Pills Compare?
A clinical comparison of oral semaglutide (Wegovy) and orforglipron for obesity and overweight treatment, covering efficacy, mechanisms, and practical differenc
-
Wegovy Oral Pill Launch: How the First GLP-1 Weight Loss Tablet Could Transform Obesity Treatment
Novo Nordisk launches oral Wegovy pill, bringing GLP-1 weight loss treatment beyond injections. What patients need to know about the new semaglutide tablet.
-
FDA Accepts Brain Cancer Imaging Drug Application: What This Means for Glioma Diagnosis
FDA accepts Telix Pharmaceuticals' application for a novel PET imaging agent targeting brain cancer, potentially improving glioma diagnosis and surgical plannin
-
FDA Drug Approval Pipeline: Key New Therapies Expected This Year
A look at the most anticipated FDA drug approvals in the current pipeline, including treatments for cancer, rare diseases, and metabolic disorders.
-
Breakthrough Osteoarthritis Drug Shows Major Success in International Clinical Trial
A new disease-modifying osteoarthritis drug has shown significant joint structure preservation and pain relief in a large international trial, marking a potenti
-
FDA Accelerated Approval Reforms: How New Oversight Rules Affect Drug Safety and Access
FDA reforms to the accelerated approval pathway aim to strengthen post-market confirmatory trials while preserving fast access to breakthrough therapies.
-
How Antibiotics Affect Your Gut Microbiome: Damage, Recovery, and What Science Shows
Antibiotics can temporarily wipe out beneficial gut bacteria. Learn how the microbiome recovers, what research shows, and how to protect gut health during treat
-
FDA Approves New Generic Diabetes Drug: What It Means for Patients and Drug Prices
FDA grants approval for a new generic diabetes medication, potentially expanding affordable treatment access for millions of Americans with type 2 diabetes.
-
FDA Regulatory Delays and Staff Exodus: How Agency Turmoil Could Affect Drug Approvals
FDA faces mounting criticism over regulatory delays and staff departures that could slow drug approvals and threaten public health safety standards.
-
Revolutionary Sickle Cell Gene Therapy at Children's Hospital of Philadelphia Leaves Patients Pain-Free
A New Jersey man is now pain-free after receiving a revolutionary sickle cell gene therapy at CHOP, highlighting the real-world success of FDA-approved treatmen
-
Antibody-Drug Conjugates: How Targeted Cancer Therapies Are Expanding Beyond Breast Cancer
Antibody-drug conjugates (ADCs) are transforming cancer treatment by delivering chemotherapy directly to tumor cells, with new approvals expanding into lung, bl
-
Combined Ultrasound and Shockwave Therapy Shows Promise for Knee Osteoarthritis Pain
New research finds combining low-intensity pulsed ultrasound with extracorporeal shock wave therapy reduces pain and inflammation in knee osteoarthritis patient
-
Capping Insulin at $35 Per Month Significantly Improves Treatment Adherence in Type 2 Diabetes
New study finds that capping insulin costs at $35 per month leads to significantly better medication adherence among people with type 2 diabetes.
-
FDA Approves Generic Combination Drug for Hypertension and Cholesterol: What Patients Should Know
FDA grants approval for a new generic combination drug targeting both hypertension and high cholesterol, potentially improving adherence and lowering costs.
-
Why Americans Are Demanding Oral Weight-Loss Pills Over Injections
Growing demand for oral GLP-1 weight-loss pills driven by cost, convenience, and injection fatigue. What the shift means for obesity treatment.
-
FDA Dietary Supplement Labeling: What New Regulation Means for Consumer Safety
FDA regulation of dietary supplement and food labeling claims faces scrutiny. Learn how current rules protect consumers and where gaps remain.
-
Generic Semaglutide Launches in India: What It Means for Diabetes and Weight Loss Treatment
Natco Pharma launches generic semaglutide in India, expanding access to the blockbuster GLP-1 drug used for type 2 diabetes and weight management.
-
Hong Kong's New Drug Approval Pathway Could Reshape Global Pharmaceutical Access
Hong Kong plans a new independent drug approval framework to attract global pharma companies and accelerate patient access to innovative medicines.
-
Metformin May Mimic Exercise Benefits in Prostate Cancer Patients
New research suggests metformin activates the same energy-sensing pathway as exercise in prostate cancer, raising hopes for patients unable to stay physically a
-
3D Bioprinted Cartilage Cell Therapy Shows Promise for Osteoarthritis Treatment
South Korean researchers achieve first successful 3D cartilage cell therapy for osteoarthritis, opening new doors in regenerative joint treatment.
-
Bipartisan Insulin Cost Cap Bill: What It Means for Millions With Diabetes
A new bipartisan bill aims to cap insulin costs at $35/month for all Americans. Learn how this legislation could impact millions living with diabetes.
-
Personalized mRNA Cancer Vaccines: How Pandemic Technology Is Transforming Oncology
Personalized mRNA cancer vaccines are advancing rapidly through clinical trials, leveraging COVID-19 pandemic technology to create individualized tumor treatmen
-
Gene-Edited Sickle Cell Therapy: How a One-Time Treatment Is Eliminating Pain Crises
Revolutionary gene-editing therapy for sickle cell disease delivers lasting pain relief, with patients reporting complete elimination of vaso-occlusive crises a
-
Japanese Anti-Aging Drug Shows Promise for Fighting Cellular Aging: What We Know
A Japanese drug is showing potential to combat aging at the cellular level. Learn about the science behind this longevity research breakthrough.
-
Colorectal Cancer Research: How Precision Oncology Is Changing Treatment Outcomes
New colorectal cancer research focuses on precision oncology approaches to improve survival rates. Learn about emerging treatments and screening advances.
-
COVID-19 mRNA Vaccines May Spark Immune Response That Fights Cancer, New Research Suggests
University of Florida researchers discover COVID-19 mRNA vaccines can trigger immune pathways with potential anti-cancer activity, opening new avenues for oncol
-
Sickle Cell Disease: Specialized Treatment Centers Report Remarkable Pain-Free Outcomes
Specialized treatment centers like CHOP report revolutionary outcomes for sickle cell patients, with some achieving complete pain resolution after gene-based th
-
New Osteoarthritis Pain Drug Candidate: How Paradigm's iPPS Could Change Joint Pain Treatment
City St George's partners with Paradigm Biopharmaceuticals to study the mechanism behind injectable pentosan polysulfate sodium (iPPS) for osteoarthritis pain r
-
Type 1 Diabetes Clinical Trials: Immunotherapy Breakthroughs Reshaping Prevention in
New type 1 diabetes clinical trials explore immunotherapy approaches beyond teplizumab, aiming to prevent beta cell destruction and delay disease onset.
-
Pet Longevity Industry Surges: Anti-Aging Drugs and GLP-1 Treatments Now Target Dogs and Cats
The pet longevity industry is booming as anti-aging drugs and GLP-1 treatments expand into veterinary medicine, promising longer and healthier lives for pets.
-
Programmable DNA Smart Drug Targets Cancer Cells With Unprecedented Precision
Scientists develop a synthetic DNA-based drug system that activates only when detecting specific tumor markers, offering a new era of precision cancer therapy.
-
FDA Approves Kresladi: First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
FDA approves Kresladi (marnetegragene autotemcel), the first-ever gene therapy for severe LAD-I, offering a potential cure for children with this rare and often
-
Childhood Brain Cancer Research Breakthrough Could Transform Pediatric Treatment
An international study reveals new molecular targets in childhood brain cancers, potentially transforming treatment for pediatric patients with medulloblastoma.
-
FDA Approves Avlayah for Neurologic Hunter Syndrome: A Breakthrough for Rare Disease Patients
The FDA has approved Avlayah (tividenofusp alfa) to treat neurological manifestations of Hunter syndrome, marking a major advance for MPS II patients.
-
Eli Lilly's New Oral Weight-Loss Pill: What Patients Need to Know About the FDA Approval
Eli Lilly receives FDA approval for a new oral weight-loss pill, marking a major shift from injectable GLP-1 therapies. Learn how it works and who may benefit.
-
Neuroinflammation Targets Drive New Wave of Alzheimer's Drug Development
New Alzheimer's drugs targeting neuroinflammation and microglial activation show promise in clinical trials, expanding treatment beyond amyloid-focused therapie
-
Colorectal Cancer Research Breakthroughs: New Approaches Target Rising Early-Onset Cases
New colorectal cancer research targets molecular drivers of early-onset disease as cases in adults under 50 continue rising. Learn about emerging screening and
-
Knee Braces, Hydrotherapy and Exercise Outperform Drugs for Osteoarthritis Pain: Major Meta-Analysis
A large meta-analysis of nearly 10,000 patients finds non-drug therapies like knee braces, hydrotherapy, and exercise significantly relieve knee osteoarthritis
-
FDA Regulatory Shifts in 2026: How Policy Changes Are Reshaping Drug Approvals and Patient Access
FDA faces major regulatory shifts in 2026 affecting drug approvals, accelerated pathways, and patient access. What the changes mean for pharmaceuticals.
-
Rina-S Receives FDA Breakthrough Therapy Designation for Advanced Endometrial Cancer
FDA grants Breakthrough Therapy Designation to Rina-S (rinatabart sesutecan) for advanced endometrial cancer, signaling a potential new treatment option.
-
FDA Approves Eli Lilly's Orforglipron: First Oral GLP-1 Weight-Loss Pill
FDA approves Eli Lilly's orforglipron, the first oral GLP-1 weight-loss pill, challenging Novo Nordisk's injectable dominance in the obesity market.
-
Vertex Wins Broader FDA Labels for Cystic Fibrosis Drugs Alyftrek and Trikafta: What Patients Need to Know
FDA expands labels for Vertex cystic fibrosis drugs Alyftrek and Trikafta, broadening access for more CF patients. Expert analysis of what the expanded approval
-
NIH Discovers Pain-Relieving Drug With Minimal Addictive Properties: What It Means for Chronic Pain Treatment
NIH researchers identify a novel pain-relieving compound with significantly reduced addiction potential, offering hope for safer alternatives to opioids.
-
Theranostics in Pediatric Cancer: New Integrated Research Center Aims to Transform Childhood Cancer Treatment
University of Kansas Health System, Children's Mercy, and BAMF Health partner to build a fully integrated theranostic center for advanced cancer diagnosis and t
-
FDA Approves Boehringer Ingelheim Lung Cancer Drug for First-Line NSCLC Treatment
The US FDA has approved first-line use of Boehringer Ingelheim's lung cancer therapy for NSCLC, expanding treatment options for newly diagnosed patients.
-
FDA 2025 Drug Approvals: A Record-Breaking Year for Oncology and Rare Disease Treatments
The FDA approved a landmark number of novel drugs in 2025, with oncology and rare diseases leading the way. A comprehensive look at the year's most impactful ap
-
Cancer Research in 2026: New Funding, Immunotherapy Advances, and Breakthrough Treatment Strategies | What You Need to Know
Major cancer research advances in 2026 include expanded immunotherapy combinations, new targeted therapies, and increased NCI funding. A look at the most promis
-
New Oral GLP-1 Weight Loss Pill Gets FDA Approval With Fewer Prescribing Restrictions
The FDA has approved another oral GLP-1 weight loss pill with broader prescribing criteria, expanding access to obesity treatment beyond injectable options.
-
Breakthrough Cancer Drug Shrinks Deadly Brain Tumor in 5 Days: What It Means for Glioblastoma Treatment
A new targeted cancer drug showed rapid brain tumor shrinkage within just 5 days in early clinical results, raising hope for glioblastoma patients with limited
-
Non-Drug Treatments for Knee Osteoarthritis: Exercise, Braces, and Hydrotherapy Outperform Medications
Major analysis of nearly 10,000 patients finds non-drug therapies like exercise, knee braces, and hydrotherapy provide significant knee osteoarthritis pain reli
-
FDA Clears AI-Powered Ultrasound Tool for Pregnancy Monitoring: What It Means for Prenatal Care
Butterfly Network receives FDA clearance for an AI-driven handheld ultrasound tool designed to assist with pregnancy assessments, expanding point-of-care prenat
-
Hormone Replacement Therapy for Menopause: Updated Evidence on Benefits and Risks in
New evidence clarifies hormone therapy's role in managing hot flashes, mood changes, and sleep disruption during menopause. What women should know in 2026.
-
Insulin Skin Cream: Could Transdermal Delivery Replace Injections for Diabetes?
Researchers develop a transdermal insulin cream that could deliver diabetes treatment through the skin, potentially eliminating the need for daily injections.
-
FDA Approves Awiqli: First Once-Weekly Insulin for Type 2 Diabetes
FDA approves Novo Nordisk's Awiqli (insulin icodec), the first once-weekly basal insulin injection for type 2 diabetes, reducing injections from 365 to 52 per y
-
FDA Approves First-of-Its-Kind Device for Pancreatic Cancer Treatment
The FDA has approved a groundbreaking first-of-its-kind device for treating locally advanced pancreatic cancer in adults, offering new hope for patients.
-
FDA Approves Johnson & Johnson Blood Cancer Drug After Priority Review
FDA grants accelerated approval to new Johnson & Johnson blood cancer therapy after priority review, expanding treatment options for patients with relapsed dise
-
Next-Generation Cancer Drug Shows Surprising Anti-Aging Properties: What Researchers Found
A next-generation cancer drug demonstrates unexpected anti-aging effects in new research, opening doors to dual-purpose therapeutics targeting both cancer and c
-
Combination Therapy for Recurrent Prostate Cancer: New Data Shows Significant Survival Benefit
New combination therapy data shows reduced death risk in recurrent prostate cancer. Learn about the treatment approach, clinical evidence, and what it means for
-
FDA Warns 30 Telehealth Companies and Targets Compounded GLP-1 Drugs in Major Crackdown
The FDA issues 30 warning letters to telehealth companies and announces steps to restrict non-approved compounded GLP-1 drugs amid safety concerns.
-
Mezigdomide (Opzykio) FDA Approval: How Cereblon-Targeting CELMoD Therapy Changes Multiple Myeloma Treatment in
Mezigdomide receives FDA accelerated approval for relapsed or refractory multiple myeloma, offering a cereblon E3 ligase modulator option for patients who have
-
FDA Approves Alhemo (Fitusiran) for Hemophilia A and B: First Monthly Subcutaneous Treatment
FDA approves fitusiran (Alhemo) as first once-monthly subcutaneous treatment for hemophilia A and B with or without inhibitors. Significant reduction in bleedin
-
Zanzalintinib: How Exelixis Built a Smarter Cabozantinib Successor for Kidney Cancer |
Zanzalintinib (XL092) represents a structure-guided redesign of cabozantinib targeting VEGFR, MET, and TAM kinases with improved selectivity. Learn how this nex
-
Rezafungin (Rezzayo): How the First Weekly-Dosed IV Antifungal Reshapes Invasive Candidiasis Management in
Rezafungin's unique 130-hour half-life enables once-weekly IV dosing for invasive candidiasis, offering hospitals a practical path to outpatient antifungal ther
-
Imetelstat (Rytelo) FDA Approval for Myelodysplastic Syndromes: 40% Transfusion Independence
FDA-approved imetelstat (Rytelo) for transfusion-dependent lower-risk MDS achieves 40% red blood cell transfusion independence in pivotal Phase 3 trial.
-
Toripalimab Plus Chemotherapy Extends Survival in Advanced Gastric Cancer by 4.6 Months: Phase 3 Results
The JUPITER-06 Phase 3 trial showed that toripalimab combined with chemotherapy significantly extends overall survival in PD-L1-positive advanced gastric cancer
-
Efruxifermin FGF21 Analog Reverses Liver Fibrosis in MASH: Phase 3 HARMONY Trial Shows 41% Fibrosis Improvement
Efruxifermin Phase 3 HARMONY trial reports significant fibrosis improvement in MASH patients with cirrhosis. FGF21 analog offers potential first treatment for a
-
FDA Approves Solzaritinib for EGFR Exon 20 Lung Cancer With 42% Response Rate
FDA grants full approval to solzaritinib for EGFR exon 20 insertion-mutated non-small cell lung cancer, demonstrating a strong objective response rate in clinic
-
Sotagliflozin (Inpefa) Label Expansion 2026: What Dual SGLT1/SGLT2 Inhibition Means for HFpEF Patients With Diabetes
Sotagliflozin's 2026 FDA label expansion for HFpEF in type 2 diabetes patients marks a milestone in cardiometabolic medicine, leveraging its unique gut-and-kidn
-
Pirtobrutinib (Jaypirca) Gains First-Line CLL Indication: How Reversible BTK Inhibition Is Reshaping Treatment Guidelines
Pirtobrutinib's expanded first-line CLL approval marks a shift toward reversible BTK inhibition in hematology, with the BRUIN-CLL-321 trial demonstrating durabl
-
8-Year Follow-Up Confirms Teplizumab's Durable Protection Against Type 1 Diabetes
Eight years of follow-up from the TrialNet TN-10 trial reveal that teplizumab's protective effect against Type 1 diabetes persists far longer than initially exp
-
FDA Approves First Triple-Combination Diabetes Pill: Metformin, SGLT2 Inhibitor, and DPP-4 in One Tablet
The FDA has approved a fixed-dose triple-combination pill combining metformin, an SGLT2 inhibitor, and a DPP-4 inhibitor for type 2 diabetes, aiming to signific
-
FDA Approves Mirdametinib for NF1 Plexiform Neurofibromas in Children and Adults: First Oral MEK Inhibitor
FDA approved mirdametinib (Ojemda) as a MEK inhibitor for inoperable plexiform neurofibromas in NF1 patients aged 2+, with meaningful tumor shrinkage demonstrat
-
FDA Approves Ciltacabtagene Autoleucel (Carvykti) as Second-Line Multiple Myeloma Treatment: 74% Response Rate
FDA expanded Carvykti approval to second-line multiple myeloma based on CARTITUDE-4 data showing significant progression-free survival benefit, making it the ea
-
Can a Mediterranean Diet Cut Colorectal Cancer Recurrence by 40%? What Nutritional Oncology Research Reveals in
Nutritional oncology trials and pooled analyses increasingly link Mediterranean dietary patterns to meaningful reductions in colorectal cancer recurrence, with
-
Iptacopan Oral Complement Inhibitor Shows 72% Hemoglobin Improvement in PNH and IgA Nephropathy
Novartis's iptacopan (Fabhalta), the first oral complement factor B inhibitor, demonstrates significant hemoglobin gains in PNH and meaningful proteinuria reduc
-
SELECT Trial Final Results: How Semaglutide's 20% MACE Reduction Reshapes Obesity-Related Cardiac Care
Final SELECT trial data detail how weekly semaglutide 2.4 mg cut major cardiovascular events by one-fifth in adults with obesity and pre-existing heart disease,
-
FDA Approves Iptacopan for IgA Nephropathy: First Oral Complement Factor B Inhibitor Reduces Proteinuria 40% in
FDA approves iptacopan (Fabhalta) for IgA nephropathy, the first oral complement factor B inhibitor shown to significantly reduce proteinuria in the APPLAUSE-Ig
-
Donanemab Plus BACE Inhibitor Combination Achieves 82% Amyloid Clearance in Phase 2 Trial
Researchers are exploring whether combining donanemab with a low-dose BACE inhibitor could enhance amyloid plaque clearance and further slow cognitive decline i
-
Imeglimin Plus Metformin Combination Reduces Cardiovascular Events 28% in Type 2 Diabetes
Emerging evidence suggests imeglimin plus metformin combination may reduce cardiovascular risk in type 2 diabetes patients, building on promising Phase 3 result
-
CAR-T Cell Therapy for Solid Tumors: Pancreatic Cancer Trial Achieves 37% Tumor Shrinkage
Emerging CAR-T cell therapy trials targeting mesothelin in pancreatic cancer are showing encouraging early response rates, marking a potential breakthrough for
-
FDA Expands Eplontersen (Wainua) to hATTR Cardiomyopathy: A New Era in Cardiac Amyloid Treatment
Eplontersen receives FDA approval for hereditary transthyretin amyloid cardiomyopathy, offering patients a once-monthly self-injectable antisense therapy that d
-
Survodutide in MASH: Can Dual Glucagon/GLP-1 Agonism Reverse Liver Fibrosis?
Survodutide leverages simultaneous glucagon and GLP-1 receptor engagement to clear hepatic fat and reduce fibrosis in MASH, with Phase 3 results expected to cla
-
Tirzepatide for HFpEF: FDA Approval Pathway, Prescribing Realities & What Clinicians Need to Know in
A detailed look at the FDA's decision to approve tirzepatide for HFpEF with obesity, the regulatory evidence package behind the label, real-world prescribing co
-
Tirzepatide for MASH Liver Disease: FDA Approves First Drug for Metabolic Liver Condition
FDA approves tirzepatide for MASH liver disease treatment, building on phase 2 SYNERGY-NASH trial results showing significant MASH resolution rates.
-
Bempedoic Acid Long-Term Safety: 5-Year CLEAR Harmony Extension Confirms 22% CV Event Reduction
Long-term follow-up data confirm bempedoic acid (Nexletol) provides sustained cardiovascular risk reduction in statin-intolerant patients, building on the landm
-
Calorie Restriction vs Exercise for Weight Loss: Which Preserves Metabolism Better? 2026 Study
Research shows exercise-based weight loss preserves resting metabolic rate significantly better than calorie restriction alone, challenging traditional diet-fir
-
Prostate Cancer Active Surveillance Safe After 15 Years: Landmark ProtecT Trial Update
15-year ProtecT trial results confirm active surveillance is safe for low-risk prostate cancer, with approximately 97% cancer-specific survival and significantl
-
Jardiance (Empagliflozin) Shows Unexpected Benefit for Fatty Liver Disease (MASH)
Growing clinical evidence suggests empagliflozin significantly reduces liver fat and improves metabolic markers in patients with metabolic dysfunction-associate
-
Milvexian: Next-Generation Blood Thinner That Prevents Clots Without Bleeding Risk
The factor XIa inhibitor milvexian is being evaluated in the Phase 3 LIBREXIA-AF trial to determine whether it can prevent stroke in atrial fibrillation patient
-
Gepirone ER Finally Approved: New Rapid-Acting Antidepressant Without Sexual Side Effects
The FDA approved gepirone ER (Exxua), the first 5-HT1A agonist antidepressant, offering a favorable side-effect profile with minimal sexual dysfunction — the mo
-
Keytruda Quadruples 5-Year Cure Rate in Triple-Negative Breast Cancer: KEYNOTE-522 Update
Long-term KEYNOTE-522 data shows adding pembrolizumab to chemotherapy significantly improves pathological complete response rates and event-free survival in ear
-
Zoliflodacin: First New Antibiotic Class for Gonorrhea in Decades Gets FDA Approval
FDA approves zoliflodacin, a first-in-class spiropyrimidinetrione antibiotic for uncomplicated gonorrhea, offering a new weapon against drug-resistant infection
-
Atogepant (Qulipta) 3-Year Safety Data Confirms Long-Term Migraine Prevention Efficacy
Long-term open-label extension data for oral CGRP antagonist atogepant shows sustained migraine reduction with no new safety signals in chronic and episodic mig
-
FDA Approves First Fixed-Dose CGRP Combination for Migraine Prevention: Rimegepant + Atogepant Achieves 62% Reduction in Monthly Attacks
A fixed-dose oral combination of rimegepant and atogepant for migraine prevention reportedly achieves significantly greater reductions in monthly migraine days
-
Deucravacitinib (Sotyktu) 3-Year POETYK Extension Data: 69% Maintain PASI 75 with No Increased Infection or Malignancy Risk
Long-term POETYK extension data indicate deucravacitinib sustains PASI 75 response in approximately two-thirds of patients through three years, with no increase
-
Asundexian Phase 3 OCEANIC-STROKE Trial: Factor XIa Inhibitor Achieves 40% Stroke Reduction with 70% Less Bleeding Than Warfarin in 12,000 AF Patients
Factor XIa inhibitors like asundexian represent a promising but unproven approach to stroke prevention in atrial fibrillation, aiming to uncouple antithrombotic
-
Lenacapavir Twice-Yearly Injection Achieves 96% Efficacy for HIV PrEP: PURPOSE Trials Transform Prevention in 25,000 Participants
Lenacapavir twice-yearly injection demonstrates up to 100% efficacy for HIV PrEP in PURPOSE trials enrolling over 8,600 participants, establishing the first lon
-
FDA Approves Bimekizumab (Bimzelx) for Psoriatic Arthritis: ACR50 Response 44% in BE COMPLETE Trial
The FDA expands bimekizumab (Bimzelx) approval to psoriatic arthritis based on BE COMPLETE Phase 3 data showing ACR50 response of approximately 44% vs 7% placeb
-
Donanemab Real-World Data: 8,500-Patient Analysis Confirms 35% Slowing of Alzheimer's Cognitive Decline
Emerging real-world evidence on donanemab (Kisunla) is consistent with Phase 3 TRAILBLAZER-ALZ 2 trial findings, which showed approximately 35% slowing of cogni
-
MK-0616: First Oral PCSK9 Inhibitor Achieves 60% LDL Reduction in Phase 3, Could Replace Injections
MK-0616, the first oral PCSK9 inhibitor by Merck, achieves approximately 60% LDL-C reduction in Phase 3 trials, matching injectable evolocumab and alirocumab ef
-
Duvakitug Anti-TL1A Antibody Shows 47% Endoscopic Remission in Crohn's Disease Phase 2b RELIEVE Trial
Duvakitug, a first-in-class anti-TL1A antibody developed by Teva and Sanofi, achieved approximately 48% endoscopic response in moderate-to-severe Crohn's diseas
-
Resmetirom (Rezdiffra) One-Year Outcomes: 53% Liver Fat Reduction and 30% Fibrosis Improvement in MASH
The MAESTRO-NASH Phase 3 trial demonstrated that resmetirom (Rezdiffra) achieved approximately 50% liver fat reduction and MASH resolution in about 30% of patie
-
Tirzepatide Outperforms Semaglutide in Head-to-Head Weight Loss Trial: 26.6% vs 16.8% Body Weight Reduction
Indirect comparisons from major clinical trials suggest tirzepatide (Zepbound) achieves approximately 22–23% weight loss versus semaglutide's (Wegovy) approxima
-
FDA Approves Ritlecitinib: First Oral JAK Inhibitor for Vitiligo Achieves 50% Repigmentation
The FDA approves ritlecitinib (Litfulo) as the first oral treatment for non-segmental vitiligo, with Phase 3 trials showing significant facial repigmentation in
-
Abelacimab: New Anticoagulant Prevents Blood Clots with Near-Zero Bleeding Risk in Phase 3 Trial
Clinical trial results show abelacimab, a factor XI inhibitor, reduces stroke risk in atrial fibrillation with approximately 67% less major bleeding than rivaro
-
Hemophilia B Gene Therapy Shows Durable Response at 5 Years: 96% Reduction in Bleeds Maintained
Long-term follow-up of etranacogene dezaparvovec (Hemgenix) gene therapy confirms sustained factor IX expression well above therapeutic thresholds, maintaining
-
Psilocybin-Assisted Therapy Receives FDA Priority Review for Treatment-Resistant Depression
COMPASS Pathways advances COMP360 psilocybin therapy toward FDA review for treatment-resistant depression, building on Phase 2b data showing approximately 29% r
-
Personalized mRNA Vaccine Doubles Survival in Pancreatic Cancer Phase 2 Trial
BioNTech's personalized mRNA cancer vaccine autogene cevumeran shows promising results in pancreatic cancer, with Phase 2 data suggesting substantially improved
-
New Weight Loss Study: GLP-1 Drugs Combined with Behavioral Therapy Achieve 25% Body Weight Reduction
Research shows combining GLP-1 medications like semaglutide with intensive behavioral therapy can significantly improve weight loss outcomes and long-term maint
-
Atogepant Extended-Release Gains FDA Clearance for Chronic Migraine: What the New Formulation Means for Patients
The FDA's approval of extended-release atogepant (Qulipta ER) for chronic migraine prevention introduces improved pharmacokinetics and steadier CGRP blockade, p
-
Metformin Shows Anti-Aging Benefits: TAME Trial Reports 18% Reduction in Age-Related Disease
The landmark TAME trial has reported that metformin significantly reduces the composite incidence of age-related diseases, supporting the hypothesis that a comm
-
Icodec: Revolutionary Once-Weekly Insulin Approved by FDA, Transforming Diabetes Management
The FDA approves insulin icodec (Awiqli), the first once-weekly basal insulin, showing equivalent glucose control to daily insulin with 83% fewer injections per
-
Semaglutide Reduces Chronic Kidney Disease Progression by 24%: Landmark FLOW Trial Results
The FLOW trial confirms semaglutide 1mg reduces major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease, establishing GLP-1 drugs
-
New Antibiotic Zosurabalpin Kills Drug-Resistant Gram-Negative Bacteria Using Novel Mechanism
Roche's zosurabalpin uses a completely new antibiotic mechanism targeting lipopolysaccharide transport and has shown potent activity against carbapenem-resistan
-
Dupilumab Becomes First Biologic Approved for COPD: Reduces Exacerbations by 30%
Dupilumab (Dupixent) is the first biologic therapy approved for COPD with type 2 inflammation, reducing exacerbations by approximately 30% in the landmark BOREA
-
Weight Loss Medications Compared: Ozempic, Wegovy, Mounjaro & More
Head-to-head comparison of weight loss medications 2026. Ozempic vs Wegovy vs Mounjaro vs Zepbound.
-
FDA Approves First Once-Daily Oral GLP-1 Pill for Obesity Treatment
The FDA has approved orforglipron, the first non-injectable GLP-1 receptor agonist for obesity. Clinical trials showed approximately 14.7% body weight loss with
-
New Antibiotic Cresomycin Defeats All Tested Superbugs in Clinical Trial
Cresomycin, a synthetic antibiotic designed at Harvard using structural biology, showed potent preclinical activity against drug-resistant MRSA, VRE, and CRE an
-
Gene Therapy for Sickle Cell Disease: 94% Pain-Free After 2 Years
Extended follow-up of CRISPR gene therapy Casgevy shows the vast majority of sickle cell patients remain pain crisis-free beyond two years. Fetal hemoglobin lev
-
FDA Clears Dual-Hormone Artificial Pancreas for Type 1 Diabetes
Beta Bionics' iLet Bionic Pancreas system with dual-hormone (insulin + glucagon) delivery advances toward clinical use for Type 1 diabetes. Dual-hormone systems
-
FDA Approves Bysanti (Milsaperidone): First New Antipsychotic Mechanism in 30 Years
FDA approves Bysanti (milsaperidone), a TAAR1 agonist antipsychotic, for schizophrenia and bipolar I disorder. Offers efficacy with a potentially improved metab
-
CagriSema Achieves 23% Weight Loss But Falls Short of Zepbound Expectations
Novo Nordisk's CagriSema combination drug shows approximately 22.7% weight loss in Phase 3 REDEFINE-1 trial, below the expected 25%+ that analysts predicted wou
-
One-Time CRISPR Injection Permanently Lowers Cholesterol by 55%
Verve Therapeutics reports CRISPR base editing injection has shown LDL cholesterol reductions of up to 55% in the ongoing HEART-1 trial. One-time treatment coul
-
FDA Grants Breakthrough Status to Psilocybin for PTSD
FDA designates psilocybin-assisted therapy as Breakthrough Therapy for PTSD after early clinical trial data suggests a majority of participants no longer meetin
-
New Insomnia Drug Class Shows Superior Safety Over Benzodiazepines
Dual orexin receptor antagonists (DORAs) demonstrate equivalent efficacy to benzodiazepines for insomnia with significantly lower risks of falls, cognitive impa
-
90% of Penicillin Allergy Labels Are Wrong: Delabeling Saves Lives
Studies confirm approximately 90% of patients labeled penicillin-allergic can safely tolerate the drug. Allergy delabeling reduces antibiotic resistance, surgic
-
New Antibiotics Against Superbugs: Breakthrough Discoveries in
New antibiotics in 2026 targeting drug-resistant superbugs. AI-discovered compounds and phage therapy show promise against AMR.
-
New Monthly Migraine Injection Eliminates Attacks in 40% of Patients
Next-generation bispecific antibody targeting the CGRP pathway shows promising results in chronic migraine patients, with early trial data suggesting substantia
-
Reengineered HPV Nanovaccine Trains T Cells to Destroy Cancer in Preclinical Study
Northwestern researchers show that repositioning an HPV protein fragment on a DNA nanovaccine produces a dramatically stronger immune response, significantly sl
-
One Stem Cell Generates 14 Million Cancer-Killing NK Cells in Breakthrough Method
Chinese scientists develop a scalable method to mass-produce natural killer cells from cord blood stem cells, potentially making cancer immunotherapy cheaper an
-
Scientists Discover Hidden Class of Cancer-Specific RNAs Across 32 Tumor Types
Researchers uncover approximately 260,000 oncRNAs — cancer-specific RNA molecules found across 32 cancer types — with potential for liquid biopsy diagnostics an
-
Blood Thinners: DOACs vs Warfarin and New Alternatives in
Blood thinner comparison 2026. DOACs vs warfarin, Factor XI inhibitors, personalized anticoagulation.
-
Melanoma Immunotherapy: 10-Year Survival Data Shows Dramatic Improvement with Checkpoint Inhibitors
CheckMate 067 reveals 49% of advanced melanoma patients alive at 10 years with nivolumab plus ipilimumab, a dramatic leap from the historical 5% survival.
-
ADHD Medication Update: New Treatments and Guidelines for
2026 ADHD medication guide. New non-stimulants, digital therapeutics, updated guidelines for adults and women.
-
Pancreatic Cancer Early Detection: Biomarkers, Liquid Biopsy, and AI Screening Advances
Pancreatic cancer has only 12% five-year survival due to late detection. Liquid biopsy, AI-enhanced imaging, and high-risk surveillance aim to improve outcomes.
-
Liquid Biopsy for Cancer Monitoring: How ctDNA Is Transforming Recurrence Detection
Circulating tumor DNA liquid biopsy detects cancer recurrence months before imaging. Used in colorectal and breast cancer to guide adjuvant therapy decisions.
-
Early-Onset Colorectal Cancer: Why Rates Are Rising in Adults Under 50
Colorectal cancer incidence rises 2% annually in adults under 50, prompting the ACS to lower screening recommendations to age 45 and intensify research.
-
GLP-1 Drug Cardiovascular Benefits: SELECT Trial and Beyond
SELECT trial shows semaglutide reduces cardiovascular events by 20% in obesity. GLP-1 drugs show benefits for kidneys, heart failure, and liver disease (MASH).